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Pancoast Tumors are another subgroup often requiring Trimodality Rx. 
In SWOG/ INT 0160 induction chemoXRT were given followed by 
resection. 111 eligible patients who were med negative including T3-4 
/ N0-1. 80 (72.1%) were T3; 31 were T4 tumors. 2 cycles of cisplatin/
etoposide W/ 45 Gy of radiation were given. There were 3 treatment 
deaths (2.7%). 95 pts were eligible for surgery (85%); 83 underwent 
thoracotomy (75%) 2 (2.4%) died postoperatively. 76 (92%) under-
went complete resection. 54 (65%) specimens showed complete/partial 
response. 2-year survival was 55%; 70% survival if complete resection 
was achieved. Finally, the role of high dose trimodality therapy for 
Superior Sulcus tumors was studied by Kwong KF, Gamliel Z, Krasna 
MJ. 36 patients with Pancoast tumor Stage IIB-IV (solitary brain met) 
were treated. R0 resection was achieved in 36 (97.3%) patients. Opera-
tive mortality was 2.7% (n = 1). High-dose radiotherapy (mean 56.9 
Gy; range, 30-70.2 Gy) was successfully tolerated in all but 1 patient. 
Pathologic complete response was found in 40.5% (n = 15) of patients. 
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Introduction: Structural imaging using CT scanning has long been the 
standard investigation for response assessment after chemotherapy, 
neoadjuvant chemoradiation or deﬁnitive radiation therapy (RT) for 
both non-small cell (NSCLC) and small cell lung cancer (SCLC). 
Changes in tumor dimensions after therapy are categorized into 
the widely-used WHO and RECIST response categories, which 
have prognostic signiﬁcance. However, CT scanning suffers from 
well-known limitations. These limitations include the relatively 
slow rate of change often observed in tumor volume after effective 
therapy, dependence on the unreliable parameter of lymph node size 
to determine involvement by tumor and an inability to distinguish 
between inactive scarring or necrotic tumor and active tumor in 
residual masses after therapy. The utility of CT may be further reduced 
by the presence of radiation pneumonitis and atelectasis, which can 
make it impossible to measure tumor size. 
Increasing numbers of studies demonstrate that functional imaging with 
18F-ﬂuorodeoxyglucose positron emission tomography (FDG-PET) 
can be more accurate for early assessment of response to treatment 
of NSCLC than structural imaging. FDG is a glucose analogue that is 
taken up and trapped at a high rate by malignant tumor cells, especially 
those of NSCLC. After intravenous injection of FDG labeled with the 
positron emitting isotope 18F, most lung cancers can be imaged using 
a PET scanner. Changes in FDG uptake after therapy may precede 
changes in tumor volume and therefore, comparison of pre and post 
therapy PET scans can provide an early semiquantitative indication of 
response.
FDG-PET Response Assessment Methodology
Therapeutic response information provided by PET is more complex 
than that provided by structural imaging and researchers continue 
to search for the best way to use it. Uptake of FDG into tumors is 
inﬂuenced by many different biological factors, including substrate 
utilization, tumor perfusion, effects of hypoxia and apoptosis , the 
viable cell fraction, the extent of inﬂammatory cell inﬁltrate and 
oncogene expression. PET scanning allows the investigator to visualize 
and measure the intensity of residual metabolic activity within a lesion 
as well as estimating its size, especially if PET/CT is used rather than 
PET alone. The feature that really distinguishes PET from structural 
imaging is its ability to integrate the effects of residual tumor volume 
and residual tumor metabolic activity into a single response assessment. 
The best methodology for determining early PET response has not yet 
been established but there are two main approaches.
Visual /Qualitative Methods
After deﬁnitive therapy, a visual estimate of response can give extreme-
ly useful prognostic information. This method is simple and widely-
used, especially in the lymphomas. It relies on the skilled perceptions 
of an experienced human observer and compares metabolic activity in 
all lesions when pre- and post-treatment PET scans, performed under 
identical conditions, are displayed side by side. Absence of residual 
uptake of FDG, or reduction in intensity of uptake to no more than that 
contained in the blood pool, denotes a complete metabolic response 
or CMR. An appreciable reduction in the intensity of uptake, in the 
absence of any new lesions, is denoted as a partial metabolic response 
or PMR. Progressive metabolic disease, or PMD, denotes any site of 
progression and if there is no appreciable change the term stable meta-
bolic disease (SMD) is used.
Semiquantitative or SUV-based Methods
There are very many possible methods for quantitative assessment of 
response to therapy based on PET 1, ranging from the simple to the 
extremely complex. None of the more complex methods has been 
widely adopted and the only parameter with widespread acceptance 
as a semiquantitative measure of lesion intensity is the standardized 
uptake value or SUV. The most commonly used SUV parameter is the 
SUVmax, derived from tissue activity at a single point in time and us-
ing the pixel with highest lesion activity. This analysis is not dependent 
on acquisition of dynamic information of the type required for kinetic 
modeling approaches. SUV measurement is affected by a variable time 
between injection and scan, by variation in time to equilibrium and by 
variation in uptake curve slope before and after therapy. Additionally 
it may be affected by blood glucose concentration, differs if weight 
or body surface area is used as a correction factor and may not give 
the same results if different scanners used. Additionally, inﬂammatory 
reactions (infection, radiation) in normal tissues may produce SUV in 
“malignant” range (SUV > 2.5). However, the absolute accuracy of the 
SUV measurement may not be a confounding factor in assessment of 
treatment response using FDG-PET if the pre- and post-treatment scans 
are performed on the same scanner under identical conditions. This 
type of assessment may give the earliest measure of response and be 
the best available method for determining response to chemotherapy or 
to neoadjuvant therapy when insufﬁcient time has elapsed for responses 
to evolve fully after therapy.
Clinical studies of PET response in NSCLC
PET Response after deﬁnitive Radiation Therapy/Chemoradiation
Data from prospective studies at Peter MacCallum Cancer Centre have 
shown that PET is superior to CT in response assessment after chemo-
radiation for NSCLC. PET and CT responses were identical in only 
40% of cases 2. Additionally, PET response was correlated powerfully 
with survival and patterns of failure 3. Pre- and post-treatment FDG-
PET scans were compared for 88 patients after concurrent platinum-
based radical chemo/RT (n=73) or radical RT alone (n=15). Follow-up 
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PET was performed at a median of 70 days after treatment. PET 
responses were; CMR n=40 (45%), PMR n=32 (36%), SMD n= 5 (6%) 
and PMD 11 (13%). Median survival for CMR and non-CMR patients 
was 31 and 11 months respectively (P=0.0001). One year survival for 
CMR and non-CMR patients was 93% and 47% respectively and 2 
years survival was 62% and 30% respectively. Attainment of CMR 
after radical RT/chemoRT for NSCLC bestowed superior freedom from 
both local and distant relapse. Other series have reported a strong corre-
lation between PET response and outcome. Increased FDG uptake can 
be observed due to inﬂammation in normal tissues after RT, but with 
careful interpretation this does not prevent accurate response assess-
ment. Recent pilot studies suggest that PET response measured during a 
course of RT has prognostic signiﬁcance and could potentially be used 
to dynamically modify RT target volumes or reﬁne dose distributions to 
target the more resistant tumor regions. 
PET response after Neoadjuvant Therapy
Several trials have investigated the correlation between early PET 
response to neoadjuvant chemotherapy 4, 5 or chemoRT 6 prior to 
surgery and histopathological response and/or survival. There have 
been conﬂicting reports of the utility of this information, but a strong 
but imperfect correlation between PET ﬁndings and histopathological 
response exists. PET information could potentially be used to select 
patients for surgery and at the very least could exclude those who have 
disease progression from unnecessary aggressive therapy.
PET response after Chemotherapy in advanced NSCLC
Because FDG PET scans can give an indication of response long before 
there are conclusive changes on CT scans, the use of PET to assess 
early response to chemotherapy in advanced NSCLC has seemed an 
attractive idea. Indeed there is evidence that a signiﬁcant early reduc-
tion in the SUV has prognostic signiﬁcance 7. PET is becoming more 
widely used in clinical trials to test investigational agents for activity. 
It may be used in routine clinical practice to allow an early change in 
chemotherapy or cessation of treatment in patients who show no signs 
of a useful response. This may prevent unnecessary toxicity in patients 
who would otherwise receive multiple cycles of chemotherapy before 
CT could show that treatment was ineffective.
Conclusions
As PET scanning becomes more widely available and accessible, it is 
likely to become the investigation of choice for response assessment in 
NSCLC in a wide range of clinical situations. 
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Exciting new therapeutic approaches for locally advanced lung cancers 
has been realized recently through a greater understanding of the cancer 
cell signaling pathway. Therapeutic agents designed to disrupt critical 
components of the growth factor signaling pathway such as the epider-
mal growth factor receptor cascade have demonstrated response rates 
of approximately 10% in patients with chemo-refractory lung cancers. 
The JBR-21 trial provided level 1 evidence that even as monotherapy, 
Tarceva, an EGFR TKI, improved survival in patients with stage IV 
NSCLC patients who progressed following chemotherapy (1). Where 
are we with targeted therapies and radiation in the management of 
non-small cell lung cancer? Preclinical data conﬁrmed that blockade 
of the EGFR pathway would enhance the cytotoxic effects of ionizing 
radiation (2). This was a rationale hypothesis since radiation appears to 
amplify EGFR signaling (3) along with other aspects of the cancer sur-
vival process including angiogenic proteins such as vascular endotheli-
al growth factor (VEGF). Recent randomized trials have conﬁrmed the 
efﬁcacy of combining an EGFR inhibitor, cetuximab, with radiotherapy 
in patients with locally advanced head and neck cancer (4). 
How can we tell who will respond to EGFR inhibition? Clinical data 
has emerged recently to assist in predicting responders versus non-re-
sponders to small molecule EGFR-TKIs. Speciﬁc characteristics that 
appear to be related to response to EGFR-TKIs include mutations to the 
EGFR domain as well as specimens that are both IHC and FISH posi-
tive for gene ampliﬁcation of the EGFR (5-9). Regarding the former, 
data emerged over the past several years that correlated mutations in 
the EGFR TK domain to geﬁtinib-responsiveness in NSCLC. Interest-
ingly, a majority of mutations in EGFR have been observed primar-
ily in the Asian population and similar ﬁndings have been seen in 
erlotinib-sensitive patients. We also are aware that mutations are more 
common in never-smokers, women, Asians, and patients with adeno-
carcinoma, likely explaining the association of these characteristics 
with TKI response. Interestingly, there is a paucity of data correlating 
mutations, or FISH positivity to response to monoclonal antibodies 
against the EGFR. Pre-clinical information has shown that epithelial to 
mesenchymal transition plays a role in correlating response to erlotinib 
in NSCLC and we have seen that in head and neck cancer as well to 
geﬁtinib (10-11). 
Currently, there are several clinical trials combining EGFR inhibitors 
with radiation in lung cancer. The RTOG (0324) has recently completed 
a Phase II trial combining chemo-radiation with cetuximab in locally 
advanced, stage III NSCLC. Ninty-three patients were entered and 87 
patients were analyzed. At ASCO 2007, early results from this study 
indicated that it was reasonably well tolerated (12). With a median 
follow-up of 14 months a response rate of 62% (n=54) was observed 
with a 12 month overall survival (OS) of 68%. Adverse events related 
to treatment include 20% of patients with grade 4 hematologic toxici-
ties and 7 patients with grade 3 esophagitis. Three patients reportedly 
died of pulmonary complications (adult respiratory distress syndrome, 
